沃森生物(300142.SZ):子公司上海澤潤收到1項發明專利證書
格隆匯7月13日丨沃森生物(300142.SZ)公佈,公司控股子公司上海澤潤於日前收到一項由中華人民共和國國家知識產權局頒發的發明專利證書。發明名稱:重組人乳頭瘤蛋白表達;專利號:ZL 2015 1 0958274.6;專利申請日:2015年12月18日;專利權期限:20年,自專利申請日起算。
該發明公開了一種密碼子優化的人乳頭狀瘤病毒主要衣殼蛋白L1編碼基因,所述基因在被轉入酵母細胞後可高效地表達重組人乳頭狀瘤病毒主要衣殼蛋白L1。該發明還公開了一種具有免疫原性的大分子,其主要由所述經密碼子優化的人乳頭狀瘤病毒主要衣殼蛋白L1編碼基因在酵母細胞中表達產生。該發明還公開了所述具有免疫原性的大分子的應用和組合物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.